NASDAQ:AKRX - Akorn Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akorn, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.75 +0.09 (+2.46 %) (As of 12/6/2019 04:00 PM ET) Add Compare Today's Range$3.67Now: $3.75▼$3.7950-Day Range$3.64MA: $4.32▼$5.2252-Week Range$2.34Now: $3.75▼$5.73Volume722,986 shsAverage Volume2.11 million shsMarket Capitalization$473.05 millionP/E RatioN/ADividend YieldN/ABeta1.88 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:AKRX Previous Symbol CUSIP00972810 CIK3116 Webhttp://www.akorn.com/ Phone847-279-6100Debt Debt-to-Equity Ratio0.07 Current Ratio0.53 Quick Ratio0.36Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$694.02 million Price / Sales0.68 Cash Flow$0.35 per share Price / Cash Flow10.66 Book Value$3.54 per share Price / Book1.06Profitability EPS (Most Recent Fiscal Year)($0.36) Net Income$-401,910,000.00 Net Margins-53.62% Return on Equity-19.95% Return on Assets-4.80%Miscellaneous Employees2,191 Outstanding Shares126,146,000Market Cap$473.05 million Next Earnings DateN/A OptionableOptionable Receive AKRX News and Ratings via Email Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AKRX Rates by TradingView Akorn (NASDAQ:AKRX) Frequently Asked Questions What is Akorn's stock symbol? Akorn trades on the NASDAQ under the ticker symbol "AKRX." How were Akorn's earnings last quarter? Akorn, Inc. (NASDAQ:AKRX) issued its quarterly earnings data on Thursday, October, 31st. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.06. The firm earned $176.24 million during the quarter, compared to analysts' expectations of $176.15 million. Akorn had a negative net margin of 53.62% and a negative return on equity of 19.95%. The business's revenue was up 6.4% on a year-over-year basis. During the same period last year, the company earned ($0.06) earnings per share. View Akorn's Earnings History. What price target have analysts set for AKRX? 4 brokers have issued 1-year price objectives for Akorn's stock. Their forecasts range from $4.00 to $11.00. On average, they anticipate Akorn's share price to reach $7.00 in the next year. This suggests a possible upside of 86.7% from the stock's current price. View Analyst Price Targets for Akorn. What is the consensus analysts' recommendation for Akorn? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn. Has Akorn been receiving favorable news coverage? Media coverage about AKRX stock has trended extremely negative this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Akorn. Are investors shorting Akorn? Akorn saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 7,650,000 shares, a decrease of 17.6% from the September 30th total of 9,280,000 shares. Based on an average daily trading volume, of 1,860,000 shares, the days-to-cover ratio is presently 4.1 days. Approximately 8.1% of the shares of the company are short sold. View Akorn's Current Options Chain. Who are some of Akorn's key competitors? Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Zogenix (ZGNX). What other stocks do shareholders of Akorn own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ). Who are Akorn's key executives? Akorn's management team includes the folowing people: Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)Dr. Bruce Kutinsky, Consultant (Age 53)Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55) Who are Akorn's major shareholders? Akorn's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (2.66%), State Street Corp (2.60%), Canyon Capital Advisors LLC (2.38%), Mackay Shields LLC (0.57%), Gabelli Funds LLC (0.35%) and Gamco Investors INC. ET AL (0.29%). Company insiders that own Akorn stock include Alan D Weinstein, John N Kapoor, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn. Which major investors are selling Akorn stock? AKRX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, State Street Corp, Assenagon Asset Management S.A., Barclays PLC, SG Americas Securities LLC, Chicago Equity Partners LLC and Gabelli Funds LLC. View Insider Buying and Selling for Akorn. Which major investors are buying Akorn stock? AKRX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Mackay Shields LLC, Canyon Capital Advisors LLC, Tibra Equities Europe Ltd, State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Gamco Investors INC. ET AL and California Public Employees Retirement System. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn. How do I buy shares of Akorn? Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Akorn's stock price today? One share of AKRX stock can currently be purchased for approximately $3.75. How big of a company is Akorn? Akorn has a market capitalization of $473.05 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn. What is Akorn's official website? The official website for Akorn is http://www.akorn.com/. How can I contact Akorn? Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected] MarketBeat Community Rating for Akorn (NASDAQ AKRX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 529 (Vote Outperform)Underperform Votes: 454 (Vote Underperform)Total Votes: 983MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/6/2019 by MarketBeat.com StaffFeatured Article: What is the Federal Reserve?